New Targeted Cancer Drug Candidate Enters Clinical Trial
A new antibody-drug conjugate is being tested in patients with advanced gastric and pancreatic cancers.
Updated on Oct. 16, 2026 in Cancer
Live Poll
Are you considering investing in pharmaceutical companies currently developing new cancer treatments?
LigaChem Biosciences has begun the first phase of a global clinical trial for LCB02A, a new antibody-drug conjugate. The trial is enrolling up to 191 patients with advanced gastric or pancreatic cancers that have not responded to standard treatments.
Why it matters
For patients with advanced solid tumors, this trial represents a new avenue for testing targeted therapies. It focuses specifically on individuals whose cancers express the CLDN18.2 protein, offering a potential treatment option for those who have exhausted existing standard care.
This Phase 1/2 clinical trial is enrolling up to 191 patients with advanced solid cancers to evaluate the safety and activity of the drug candidate LCB02A. Efficacy results and long-term safety data are not yet determined.
The players
LigaChem Biosciences
A biotechnology company focused on the development of antibody-drug conjugates for the treatment of advanced cancers.
The details
LCB02A is an antibody-drug conjugate designed to target the CLDN18.2 protein, which is often found on the surface of specific tumor cells. By identifying and binding to this protein, the drug seeks to deliver therapeutic effects directly to cancerous cells while sparing healthy tissue. The study is specifically evaluating this mechanism in patients with gastric and pancreatic cancers who have already failed standard therapies.
Timeline
October 16, 2026: The first patient was dosed in the clinical trial.
Health Landscape
Targeting the CLDN18.2 protein is a key focus in the current oncology research landscape for solid tumors. This trial adds LCB02A to the growing pipeline of antibody-drug conjugates being studied as alternatives to traditional chemotherapy for advanced gastric and pancreatic cancers.
Patients with advanced gastric or pancreatic cancer may find it helpful to discuss with their oncologist whether clinical trials targeting CLDN18.2 are appropriate for their specific diagnosis. Access to experimental therapies typically requires meeting strict clinical criteria and having exhausted standard treatment protocols.
The takeaway
Targeted therapies like LCB02A are currently being investigated to treat cancers that no longer respond to conventional care. Patients interested in emerging clinical research should maintain open communication with their oncology team regarding new, enrollment-based opportunities.
Further reading
For more on the latest research in this field, visit our Cancer section.
Source note: This article includes information reported by 조선일보.
Live Poll
Are you considering investing in pharmaceutical companies currently developing new cancer treatments?
